Seven drugs have current FDA approval for weight management
The FDA has approved seven distinct medications (or combinations) for chronic weight management as of 2025. They range from the blockbuster GLP-1 receptor agonists that dominate headlines to older drugs that still work for the right patient. Not all are equal in efficacy, cost, or side effect profile.
This post covers each one with real safety data from the FDA's own adverse event reporting system (FAERS), Medicare spending figures, and approval history pulled from Drugs@FDA records.
TL;DR
- Semaglutide (Wegovy) and tirzepatide (Zepbound) deliver the highest weight loss (15-22% of body weight) but cost $1,000+ per month without insurance
- Phentermine/topiramate (Qsymia) offers solid results (8-10%) at a fraction of the GLP-1 price
- Orlistat (Xenical/Alli) is the only OTC option but produces modest results (5-7%)
- GLP-1 drugs generated over 856,000 adverse event reports in the FAERS database for tirzepatide alone, mostly reflecting massive prescribing volume rather than outsized danger
- Medicare spent $12.9 billion on semaglutide in 2024 across 10.4 million claims
- Newer oral GLP-1s (oral semaglutide, orforglipron) may reshape the market by removing the injection barrier
How we picked and ranked these drugs
Every drug on this list meets three criteria:
- Current FDA approval specifically for chronic weight management (not off-label use for diabetes)
- Active status in the FDA's NDC directory (not withdrawn or discontinued)
- Available clinical trial data showing statistically significant weight loss versus placebo
Data sources: FDA Drugs@FDA approval records, FDA FAERS adverse event database, CMS Medicare Part D spending data (2020-2024), and published Phase III clinical trial results.
Comparison table: All FDA-approved weight loss drugs
| Drug (Brand) | Class | Route | Avg Weight Loss | Avg Monthly Cost | First Approved | FAERS Reports |
|---|---|---|---|---|---|---|
| Tirzepatide (Zepbound) | GLP-1/GIP dual agonist | Injection | 18-22% | $1,060 | May 2022 | 856,992 |
| Semaglutide (Wegovy) | GLP-1 agonist | Injection | 15-17% | $1,350 | June 2021 | 245,063 |
| Oral Semaglutide (Rybelsus) | GLP-1 agonist | Oral tablet | 10-15% | $1,000 | Sept 2019 | 239,291 |
| Liraglutide (Saxenda) | GLP-1 agonist | Injection | 8-10% | $1,400 | Dec 2014 | 88,044 |
| Phentermine/Topiramate (Qsymia) | Sympathomimetic + anticonvulsant | Oral | 8-10% | $200 | July 2012 | 66,080 |
| Naltrexone/Bupropion (Contrave) | Opioid antagonist + antidepressant | Oral | 5-8% | $300 | Sept 2014 | 25,760 |
| Orlistat (Xenical/Alli) | Lipase inhibitor | Oral | 5-7% | $60-200 | April 1999 | 17,649 |
FAERS report counts from FDA adverse event data. Higher counts correlate with prescribing volume, not necessarily higher risk.
1. Tirzepatide (Zepbound): best for maximum weight loss
At a glance: ~$1,060/month . weekly injection . best for patients who need 15%+ weight loss
Tirzepatide is the most effective weight loss drug available by the numbers. The SURMOUNT-1 trial showed 22.5% average body weight reduction at the highest dose (15mg) over 72 weeks. That translated to roughly 52 pounds for the average participant.
It works on two receptors (GLP-1 and GIP) rather than one, which appears to drive the additional weight loss over semaglutide alone. Eli Lilly received FDA approval for weight management under the brand name Zepbound in November 2023, after the drug was already approved for type 2 diabetes as Mounjaro in May 2022.
What the FAERS data shows:
| Reaction | Report Count |
|---|---|
| Incorrect dose administered | 8,081 |
| Injection site pain | 3,398 |
| Nausea | 3,131 |
| Extra dose administered | 2,519 |
| Diarrhea | 1,836 |
The top reported "adverse events" for tirzepatide are dosing errors and injection pain, not serious medical events. This pattern suggests the reporting reflects the self-injection learning curve more than drug toxicity.
Medicare spending (2024): $6.3 billion across 5.1 million claims, averaging $1,241 per fill.
Where it falls short:
- Supply constraints persisted through 2024 into early 2025
- The injection pen requires refrigeration and weekly self-administration
- Insurance coverage remains inconsistent for the weight-loss indication
Bottom line: If cost and access are not barriers, tirzepatide produces the best weight loss outcomes of any approved medication. The dual-agonist mechanism represents a genuine advance over single-target GLP-1 drugs.
2. Semaglutide injection (Wegovy): the name everyone knows
At a glance: ~$1,350/month . weekly injection . best for patients wanting proven cardiovascular benefits alongside weight loss
Semaglutide became the public face of prescription weight loss after Wegovy's approval in June 2021. The STEP 1 trial demonstrated 14.9% average weight loss over 68 weeks at the 2.4mg dose. The SELECT trial later showed a 20% reduction in major cardiovascular events, making Wegovy the first obesity drug with proven heart benefits.
Novo Nordisk markets the same molecule in three forms: Wegovy (weight loss, 2.4mg), Ozempic (diabetes, up to 2mg), and Rybelsus (oral, diabetes). Off-label Ozempic use for weight loss was widespread before Wegovy's approval and continues due to availability and insurance issues.
What the FAERS data shows:
Combining injectable and oral semaglutide reports:
| Reaction | Report Count |
|---|---|
| Nausea | 3,654 |
| Off-label use | 2,687 |
| Vomiting | 2,150 |
| Decreased appetite | 1,713 |
| Diarrhea | 314+ |
"Off-label use" appearing as a top reported event confirms what the market already knows: patients were getting semaglutide for weight loss through diabetes prescriptions long before Wegovy launched.
Medicare spending (2024): $12.97 billion for oral semaglutide plus $301 million for injectable across 10.6 million combined claims.
Where it falls short:
- Most expensive option per month among the GLP-1s (before discounts)
- Weight regain after discontinuation averages two-thirds of lost weight within a year
- Nausea and GI effects cause 5-10% of patients to discontinue
Bottom line: The most clinically proven weight loss drug with unique cardiovascular data supporting long-term use. The price premium over tirzepatide is hard to justify on efficacy alone, but the heart data matters for higher-risk patients.
3. Liraglutide (Saxenda): the first GLP-1 for weight loss
At a glance: ~$1,400/month . daily injection . best for patients who want GLP-1 benefits with more dosing flexibility
Liraglutide earned FDA approval for weight management (as Saxenda) in December 2014, making it the first GLP-1 receptor agonist approved specifically for obesity. The SCALE trial showed 8% average weight loss over 56 weeks at the 3.0mg daily dose.
The daily injection requirement puts it at a disadvantage against weekly semaglutide and tirzepatide. However, daily dosing allows faster titration and quicker dose adjustments if side effects emerge.
What the FAERS data shows:
| Reaction | Report Count |
|---|---|
| Nausea | 167 |
| Vomiting | 110 |
| Off-label use | 66 |
| Diarrhea | 65 |
| Weight increased | 56 |
Liraglutide's lower FAERS numbers (88,044 total vs. 856,992 for tirzepatide) reflect its smaller market share in the weight-loss space after newer drugs launched.
Medicare spending (2024): $203 million across 181,068 claims ($1,121 average per fill).
Where it falls short:
- Daily injections vs. weekly for newer GLP-1s
- Lower efficacy than semaglutide or tirzepatide
- Generic liraglutide biosimilars from Teva, Biocon, and Hikma are entering the market (FDA approvals in 2024-2025), which may not lower costs immediately
Bottom line: Largely superseded by weekly GLP-1 options for new starts. Still prescribed for patients already stable on it, or those who prefer smaller daily doses over a larger weekly injection.
4. Phentermine/Topiramate (Qsymia): best value for the price
At a glance: ~$200/month . daily oral capsule . best for patients who want oral dosing at lower cost
Qsymia combines a stimulant appetite suppressant (phentermine) with an anticonvulsant (topiramate) that independently suppresses appetite. The EQUIP trial showed 10.9% average weight loss at the top dose over 56 weeks. Approved in July 2012.
This is the cost-effective choice. At roughly $200/month, Qsymia delivers 8-10% weight loss for one-fifth the price of GLP-1 drugs. The tradeoff: a longer list of potential side effects and contraindications.
What the FAERS data shows:
| Reaction | Report Count |
|---|---|
| Inappropriate schedule of product administration | 137 |
| Headache | 118 |
| Paresthesia (tingling) | 101 |
| Dry mouth | 95 |
| Dizziness | 93 |
Paresthesia (tingling in hands and feet) is a topiramate-specific side effect that affects about 20% of patients. It is typically mild and resolves, but it surprises patients who were not warned.
Where it falls short:
- Contraindicated in pregnancy (topiramate causes birth defects)
- Requires REMS (Risk Evaluation and Mitigation Strategy) certification for prescribers
- Controlled substance component (phentermine is Schedule IV)
- Can raise heart rate 1-2 bpm on average
Bottom line: The best option for cost-conscious patients who are not pregnant and tolerate stimulants. Underrated relative to its efficacy data, largely because GLP-1 marketing dominates the conversation.
5. Naltrexone/Bupropion (Contrave): best for emotional eaters
At a glance: ~$300/month . oral tablet (2x daily) . best for patients with depression or food-reward-driven eating
Contrave pairs an opioid antagonist (naltrexone) with an antidepressant (bupropion). The combination targets the brain's reward system rather than gut hormones. The COR-I trial showed 6.1% average weight loss over 56 weeks. Approved September 2014.
The dual mechanism makes Contrave particularly relevant for patients whose overeating is driven by cravings, emotional eating, or food addiction patterns rather than hunger itself.
What the FAERS data shows:
| Reaction | Report Count |
|---|---|
| Nausea | 433 |
| Headache | 281 |
| Dizziness | 215 |
| Patient dissatisfaction with treatment | 199 |
| Illness | 145 |
"Patient dissatisfaction" ranking fourth is notable. Contrave requires 4 weeks of dose escalation before reaching the therapeutic dose, and many patients give up during the ramp-up period when nausea is worst and weight loss has not yet begun.
Where it falls short:
- Modest weight loss compared to GLP-1 options
- Cannot be used with opioid medications (naltrexone blocks opioid receptors)
- Carries a boxed warning for suicidal thoughts (from the bupropion component)
- 4-week titration schedule delays results
Bottom line: A reasonable oral option for patients who cannot tolerate injections and whose eating patterns involve reward-driven cravings. The psychiatric contraindications narrow the eligible population.
6. Orlistat (Xenical/Alli): the OTC option
At a glance: $60-200/month . oral capsule (3x daily with meals) . best for patients who want a non-prescription option
Orlistat works differently from every other drug on this list. It blocks intestinal lipase, preventing absorption of roughly 30% of dietary fat. The unabsorbed fat passes through the GI tract (which creates the side effects you can guess). First approved April 1999.
Available as prescription Xenical (120mg) or OTC Alli (60mg). The XENDOS trial showed 5.8% weight loss over 4 years with lifestyle changes combined.
What the FAERS data shows:
| Reaction | Report Count |
|---|---|
| Drug ineffective | 166 |
| Product complaint | 54 |
| Diarrhea | 45 |
| Upper abdominal pain | 29 |
| Steatorrhea (fatty/oily stool) | 28 |
"Drug ineffective" topping the FAERS list tells the story. Patients expecting GLP-1 level results from a lipase inhibitor are disappointed. Orlistat works, but only for patients eating high-fat diets who can tolerate the GI consequences of fat malabsorption.
Medicare spending (2024): $401,954 across 464 claims. This negligible spend confirms orlistat has been marginalized in the prescription market.
Where it falls short:
- Modest efficacy (5-7% weight loss)
- Unpleasant GI side effects (oily stools, fecal urgency, flatulence with discharge)
- Must be taken three times daily with each fat-containing meal
- Can reduce absorption of fat-soluble vitamins (A, D, E, K)
Bottom line: The only option available without a prescription (as Alli). Useful for patients who want pharmacological support without injections, high costs, or systemic drug effects. Expectations should be set at 5-7% weight loss, not the 15-22% that GLP-1s deliver.
7. Setmelanotide (Imcivree): the rare disease specialist
At a glance: ~$40,000+/month . daily injection . best for patients with genetically confirmed obesity (POMC, PCSK1, or LEPR deficiency)
Setmelanotide is in a different category. It treats obesity caused by specific rare genetic mutations, not general obesity. FDA approved it in November 2020 for patients with POMC, PCSK1, or LEPR deficiency confirmed by genetic testing. Rhythm Pharmaceuticals markets it as Imcivree.
The mechanism targets melanocortin 4 receptors (MC4R) that are dysfunctional in these patients due to upstream pathway defects. Clinical trials showed 25-30% weight loss in the genetically confirmed population.
What the FAERS data shows:
| Reaction | Report Count |
|---|---|
| Nausea | 21 |
| Off-label use | 20 |
| Skin hyperpigmentation | 16 |
| Skin discoloration | 11 |
| Vomiting | 11 |
Only 456 total reports reflect the tiny patient population. Skin darkening is an expected pharmacological effect of MC4R activation (the melanocortin pathway also regulates skin pigmentation).
Where it falls short:
- Only appropriate for rare genetic obesity (~3,000-5,000 eligible patients in the US)
- Requires genetic testing to confirm eligibility
- Extreme cost puts it in the orphan drug pricing tier
- Not effective for general/common obesity
Bottom line: Not relevant for most patients seeking weight loss medication. Critical for the small population with confirmed genetic obesity who had no effective treatment before its approval.
What about phentermine alone?
Phentermine (Adipex-P, Lomaira) is FDA-approved for short-term weight management (up to 12 weeks) but not for chronic/long-term use. It is excluded from this list because chronic use is off-label, even though many physicians prescribe it long-term in practice.
At roughly $30-50/month for generic phentermine, it remains the cheapest prescription weight loss option. The 12-week limitation exists because the original 1959 approval predated modern requirements for long-term safety data, and no sponsor has funded the trials needed to change the label.
The pipeline: what comes next
Three drugs in late development may reshape the weight loss market:
| Drug | Sponsor | Mechanism | Expected Weight Loss | Status |
|---|---|---|---|---|
| Orforglipron | Eli Lilly | Oral GLP-1 agonist | 12-14% | Phase III |
| Retatrutide | Eli Lilly | GLP-1/GIP/glucagon triple agonist | 24-27% | Phase III |
| Survodutide | Boehringer Ingelheim | GLP-1/glucagon dual agonist | 18-19% | Phase III |
Orforglipron is already in our database as a tracked drug (oral GLP-1 receptor agonist). An effective oral GLP-1 without the semaglutide-specific food timing requirements would address the biggest patient objection to current injectable options.
Retatrutide's Phase II data showing 24% weight loss at 48 weeks (TRIUMPH-2 trial) suggests the ceiling has not been reached for incretin-based therapies.
Choosing between them: a practical framework
If cost is the primary concern: Phentermine/topiramate (Qsymia) at $200/month delivers 8-10% weight loss. That is 40-50% of what GLP-1s achieve at 15-20% of the price.
If maximum weight loss is the goal: Tirzepatide (Zepbound) with 18-22% average loss. The data is clear.
If heart disease risk matters: Semaglutide (Wegovy) with the SELECT trial cardiovascular data showing 20% reduction in MACE events.
If injections are a dealbreaker: Naltrexone/bupropion (Contrave) or phentermine/topiramate (Qsymia). Oral semaglutide (Rybelsus) has weight loss data but does not yet have FDA approval specifically for weight management.
If eating is emotionally driven: Naltrexone/bupropion targets reward pathways directly.
If no prescription is desired: Orlistat (Alli) over the counter.
FAQ
How much weight can you lose on FDA-approved weight loss drugs?
Results vary by drug. GLP-1 receptor agonists (tirzepatide, semaglutide) produce 15-22% body weight loss. Older options like phentermine/topiramate deliver 8-10%, while orlistat averages 5-7%. All numbers assume continued use alongside diet and exercise.
Do you regain weight after stopping weight loss medication?
Yes. Studies show patients regain approximately two-thirds of lost weight within 12 months of stopping GLP-1 medications. The drugs suppress appetite while taken but do not permanently reset the body's weight set-point. Most physicians now consider obesity a chronic condition requiring long-term treatment.
Are GLP-1 weight loss drugs safe long-term?
Semaglutide has the longest safety record among newer GLP-1s, with data out to 5+ years. The SELECT trial (17,604 patients over 39 months) showed cardiovascular benefit and no unexpected safety signals. Tirzepatide long-term data is accumulating but is newer (approved 2022). Common side effects are GI-related: nausea, vomiting, diarrhea, and constipation.
Why are weight loss drugs so expensive?
GLP-1 receptor agonists are biologic peptides manufactured through complex fermentation processes. Patent protection prevents generic competition. The Inflation Reduction Act's Medicare negotiation provisions may eventually apply to these drugs, but current list prices remain $1,000-1,400/month. Generic biosimilar liraglutide products received FDA approval in 2024-2025, potentially previewing future competition.
Does Medicare cover weight loss drugs?
Medicare Part D historically excluded anti-obesity medications. The Treat and Reduce Obesity Act has been introduced multiple times in Congress but has not passed. However, Medicare does cover GLP-1 drugs prescribed for type 2 diabetes (Ozempic, Mounjaro). Some Medicare Advantage plans have added weight management drug coverage independently.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide made by Novo Nordisk. Ozempic is approved for type 2 diabetes (doses up to 2mg weekly). Wegovy is approved for chronic weight management (2.4mg weekly). The higher Wegovy dose produces greater weight loss. They cannot be prescribed together.
Can you get weight loss drugs without a prescription?
Orlistat (sold as Alli at 60mg) is the only FDA-approved weight loss drug available over the counter. All GLP-1 drugs, phentermine combinations, and naltrexone/bupropion require a prescription. Compounded semaglutide and tirzepatide are facing FDA enforcement actions in 2025-2026.
How do adverse event reports (FAERS) relate to drug safety?
FAERS is a voluntary reporting system. High report counts do not mean a drug is more dangerous. They reflect prescribing volume, media attention, and reporting culture. A drug prescribed to 10 million patients will generate far more reports than one prescribed to 100,000, even if the per-patient risk is identical. Use FAERS data for signal detection and trend analysis, not absolute risk assessment.
Data source and methodology
All drug data in this post comes from three FDA and CMS sources:
- FDA Drugs@FDA: approval dates, application types, sponsors
- FDA FAERS: adverse event report counts and reaction types
- CMS Medicare Part D: spending and claims data (2020-2024)
Clinical trial efficacy numbers reference published Phase III results (SURMOUNT, STEP, SCALE, EQUIP, COR-I, XENDOS trials). Cost estimates reflect approximate 2025 list prices before insurance or discount programs.
Want this data as an API? MyfitByte aggregates FDA approval records, adverse event reports, and Medicare spending data into a single queryable interface. Join the waitlist for early access.
Related reading:
Published on 2026-08-20 · 16 min read
← Back to all articles